• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后无复流相关临床变量:PERSTEMI I和II研究的二次分析]

[Clinical variables associated with no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction: Secondary analysis of the PERSTEMI I and II study].

作者信息

Paredes-Paucar Cynthia, Custodio-Sánchez Piero, Chacón-Diaz Manuel

机构信息

Instituto del Corazón, Clínica San Pablo. Lima, Perú. Instituto del Corazón Clínica San Pablo Lima Perú.

Hospital Almanzor Aguinaga Asenjo. Chiclayo, Perú. Hospital Almanzor Aguinaga Asenjo Chiclayo Perú.

出版信息

Arch Peru Cardiol Cir Cardiovasc. 2022 Dec 31;3(4):196-203. doi: 10.47487/apcyccv.v3i4.253. eCollection 2022 Oct-Dec.

DOI:10.47487/apcyccv.v3i4.253
PMID:37351015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10284576/
Abstract

OBJECTIVE

To determine the clinical factors associated to no-reflow after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) in Peru.

MATERIALS AND METHODS

Case - control retrospective study, derived from the PERSTEMI (Peruvian Registry of ST-elevation myocardial infarction) I and II study. Cases (group 1) were those patients who presented no-reflow after PCI, defined by a TIMI flow < 3, and controls (group 2) were those with a TIMI 3 flow after the intervention. Clinical and angiographic variables were compared between both groups, and a multivariate analysis was performed looking for associated factors to no-reflow.

RESULTS

We included 75 cases and 304 controls. The incidence of no-reflow was 19.8%. There was a higher frequency of no-reflow in patients with primary PCI compared to the pharmacoinvasive strategy, in patients with one-vessel disease and in those with TIMI 0 before PCI. In-hospital mortality and heart failure were higher in patients with no-reflow (21.3% vs. 2.9% and 45.3% vs. 16.5, respectively; p<0.001). After the multivariate analysis, the ischemia time > 12 hours, Killip Kimball (KK) > I, TIMI 0 before PCI, and one-vessel disease were the factors significantly associated with no-reflow after PCI.

CONCLUSIONS

The ischemia time greater than 12 hours, the highest KK score, the presence of an occluded culprit artery (TIMI 0) before PCI and an one-vessel disease, were factors independently associated to no-reflow in patients with STEMI in Peru.

摘要

目的

确定秘鲁ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后无复流相关的临床因素。

材料与方法

病例对照回顾性研究,源自PERSTEMI(秘鲁ST段抬高型心肌梗死登记研究)I和II研究。病例组(第1组)为PCI术后出现无复流的患者,定义为心肌梗死溶栓试验(TIMI)血流<3,对照组(第2组)为介入治疗后TIMI血流3级的患者。比较两组的临床和血管造影变量,并进行多因素分析以寻找与无复流相关的因素。

结果

我们纳入了75例病例和304例对照。无复流发生率为19.8%。与药物介入策略相比,直接PCI患者、单支血管病变患者以及PCI术前TIMI 0级患者的无复流发生率更高。无复流患者的院内死亡率和心力衰竭发生率更高(分别为21.3%对2.9%和45.3%对16.5%;p<0.001)。多因素分析后,缺血时间>12小时、Killip Kimball(KK)分级>I、PCI术前TIMI 0级以及单支血管病变是PCI术后无复流的显著相关因素。

结论

缺血时间大于12小时、KK评分更高、PCI术前存在罪犯血管闭塞(TIMI 0)以及单支血管病变,是秘鲁STEMI患者无复流的独立相关因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/10284576/ca781ff932d0/apcyccv-3-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/10284576/ca781ff932d0/apcyccv-3-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/10284576/ca781ff932d0/apcyccv-3-196-g001.jpg

相似文献

1
[Clinical variables associated with no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction: Secondary analysis of the PERSTEMI I and II study].[ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后无复流相关临床变量:PERSTEMI I和II研究的二次分析]
Arch Peru Cardiol Cir Cardiovasc. 2022 Dec 31;3(4):196-203. doi: 10.47487/apcyccv.v3i4.253. eCollection 2022 Oct-Dec.
2
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.入院时红细胞分布宽度-血小板比值对接受直接经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者无复流现象的预测价值
Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27.
3
The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.入院时 TIMI 风险指数对 STEMI 患者直接经皮冠状动脉介入治疗后血管造影无复流的预测价值。
Turk J Med Sci. 2016 Apr 19;46(3):604-13. doi: 10.3906/sag-1411-157.
4
Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction.冠状动脉扩张是 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流的独立预测因子。
Int J Cardiol. 2018 Aug 15;265:12-17. doi: 10.1016/j.ijcard.2018.04.120. Epub 2018 Apr 25.
5
Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.经皮冠状动脉介入治疗 ST 段抬高型心肌梗死无复流现象的预测因素。
Ann Cardiol Angeiol (Paris). 2021 Jun;70(3):136-142. doi: 10.1016/j.ancard.2021.04.004. Epub 2021 May 4.
6
A score system to predict no-reflow in primary percutaneous coronary intervention: The PIANO Score.一种预测直接经皮冠状动脉介入治疗中无复流现象的评分系统:PIANO评分。
Eur J Clin Invest. 2022 Feb;52(2):e13686. doi: 10.1111/eci.13686. Epub 2021 Oct 11.
7
The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.急性ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗时血清类风湿因子水平与无复流现象的关系
J Clin Lab Anal. 2018 Nov;32(9):e22598. doi: 10.1002/jcla.22598. Epub 2018 Jun 26.
8
Frequency of Thrombolysis in Myocardial Infarction III Flow in Patients With Primary Percutaneous Coronary Intervention: Not All Culprit Vessels Are Completely Occluded in ST Elevation Myocardial Infarction.接受直接经皮冠状动脉介入治疗的心肌梗死溶栓治疗III级血流患者的发生率:并非所有罪犯血管在ST段抬高型心肌梗死中均完全闭塞。
Cureus. 2020 Dec 12;12(12):e12036. doi: 10.7759/cureus.12036.
9
Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.纤维蛋白原与白蛋白比值对预测接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流及短期预后的价值
Heart Vessels. 2019 Oct;34(10):1600-1607. doi: 10.1007/s00380-019-01399-w. Epub 2019 Apr 16.
10
Correlation between endothelial dysfunction and occurrence of no-reflow in patients undergoing post-thrombolysis early invasive percutaneous intervention for ST-elevation myocardial infarction.ST段抬高型心肌梗死溶栓后早期有创经皮介入治疗患者内皮功能障碍与无复流发生的相关性
Egypt Heart J. 2022 Sep 30;74(1):70. doi: 10.1186/s43044-022-00309-2.

本文引用的文献

1
[Treatment of acute myocardial infarction in Peru and its relationship with in-hospital adverse events: results from the second peruvian registry of ST-segment elevation myocardial infarction (PERSTEMI-II).].[秘鲁急性心肌梗死的治疗及其与院内不良事件的关系:秘鲁ST段抬高型心肌梗死第二次注册研究(PERSTEMI-II)的结果。]
Arch Peru Cardiol Cir Cardiovasc. 2021 Jun 30;2(2):86-95. doi: 10.47487/apcyccv.v2i2.132. eCollection 2021 Apr-Jun.
2
[One-year survival among patients with ST-elevation myocardial infarction in Peru].[秘鲁ST段抬高型心肌梗死患者的一年生存率]
Arch Peru Cardiol Cir Cardiovasc. 2022 Jun 27;3(2):53-59. doi: 10.47487/apcyccv.v3i2.218. eCollection 2022 Apr-Jun.
3
One-year results from the Assessing MICRO-vascular resistances IMR to predict outcome in ST-elevation myocardial infarction patients with multivessel disease undergoing primary PCI (AMICRO) trial.
评估微血管阻力以预测多支血管病变的ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗(AMICRO)试验的一年结果。
Front Cardiovasc Med. 2022 Dec 2;9:1051174. doi: 10.3389/fcvm.2022.1051174. eCollection 2022.
4
Predictors in no-reflow phenomenon in acute myocardial infarction with ST-segment elevation.ST 段抬高型急性心肌梗死无复流现象的预测因素。
Arch Cardiol Mex. 2022;92(4):461-468. doi: 10.24875/ACM.21000346.
5
Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country.在一个拉丁美洲国家,采用直接经皮冠状动脉介入治疗或药物侵入性策略治疗 ST 段抬高型心肌梗死的结果。
BMC Cardiovasc Disord. 2022 Jun 29;22(1):296. doi: 10.1186/s12872-022-02730-6.
6
Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention.机器学习预测行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者无复流和住院死亡率。
BMC Med Inform Decis Mak. 2022 Apr 24;22(1):109. doi: 10.1186/s12911-022-01853-2.
7
"No-Reflow" Phenomenon: A Contemporary Review.“无复流”现象:当代综述
J Clin Med. 2022 Apr 16;11(8):2233. doi: 10.3390/jcm11082233.
8
Mechanism and potential treatment of the "no reflow" phenomenon after acute myocardial infarction: role of pericytes and GPR39.急性心肌梗死后“无再流”现象的机制及潜在治疗方法:周细胞和 GPR39 的作用。
Am J Physiol Heart Circ Physiol. 2021 Dec 1;321(6):H1030-H1041. doi: 10.1152/ajpheart.00312.2021. Epub 2021 Oct 8.
9
Fibrinolysis Therapy Combined with Deferred PCI versus Primary Angioplasty for STEMI Patients During the COVID-19 Pandemic: Preliminary Results from a Single Center.COVID-19大流行期间STEMI患者纤溶治疗联合延迟PCI与直接PCI的比较:单中心初步结果
Int J Gen Med. 2021 Jan 19;14:201-209. doi: 10.2147/IJGM.S292901. eCollection 2021.
10
Featuring: Eugene Braunwald.主演:尤金·布劳纳尔德。
Eur Cardiol. 2019 Jul 11;14(2):130-133. doi: 10.15420/ecr.2019.14.2.CM1. eCollection 2019 Jul.